The still long and winding road to neoadjuvant sytemic therapy as the standard of care in breast cancer

Breast Care

Volumn 1, Issue 6, 2006, Pages 352-357

  Greil, R ^a,b  

^a Laboratory of Immunological and Molecular Cancer Research   (Austria)

^b Univ Klin fur Innere Medizin III Mit Hamatologje   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; NAVELBINE; TACROLIMUS; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; DRUG RESEARCH; EDITORIAL; FALSE POSITIVE RESULT; HUMAN; LUNG CANCER; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REPRODUCIBILITY; THERAPY DELAY; TUMOR VOLUME;

EID: 33845909298     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000098106     Document Type: Editorial

References (49)

1. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-1492.
2. Fisher B, Gunduz N, Saffer EA: Interrelation between tumor cell proliferation and 17-fluoresceinated estrone binding following primary tumor removal, radiation, cyclophosphamide, or tamoxifen. Cancer Res 1983;43:5244-5247.
3. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001.
4. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-1949.
5. Schwartz GF, Hortobagyi GN: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA. Cancer 2004;100:2512-2532.
6. Mauri D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005;97:188-194.
7. Popat S, Smith IE: Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005;97:858; author reply 858-859.
8. Hutcheon AW HS: Primary systemic chemotherapy of large and locally advanced breast cancer. American Society of Clinical Oncology 2004 Educational Book 2004:63-79.
9. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group. J Clin Oncol 1999;17:1413-1424.
10. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
11. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The gepartrio pilot study. Ann Oncol 2005;16:56-63.
12. Hutcheon AW, Heys SD, Sarkar TK: Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003;79 (Suppl 1):S19-S24.
13. Smith IE, Lipton L: Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001;2:561-570.
14. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005;23:8331-8339.
15. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA: Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results. Breast J 2006;12:159-164.
16. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE: Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243:257-264.
17. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol b-27. J Clin Oncol 2003;21:4165-4174.
18. Belli P, Costantini M, Malaspina C, Magistrelli A, Latorre G, Bonomo L: Mri accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 2006;61:946-953.
19. Fukutomi T: Clinical practice and outcome of breast-conserving treatment: The effectiveness of preoperative systemic chemotherapy. Breast Cancer 2006;13:147-151.
20. Bear HD, Anderson S, Smith RE, Geyer CE, Jr., Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National surgical adjuvant breast and bowel project protocol b-27. J Clin Oncol 2006;24:2019-2027.
21. Dontu G, Liu S, Wicha MS: Stem cells in mammary development and carcinogenesis: Implications for prevention and treatment. Stem Cell Rev 2005;1:207-214.
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
23. Ponti D, Zaffaroni N, Capelli C, Daidone MG: Breast cancer stem cells: An overview. Eur J Cancer 2006;42:1219-1224.
24. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
25. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-456.
26. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-2749.
27. Morrow M, Goldstein L: Surgery of the primary tumor in metastatic breast cancer: Closing the barn door after the horse has bolted? J Clin Oncol 2006;24:2694-2696.
28. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 2001;358:966-970.
29. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Jr., Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659.
30. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Jr., Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project b-18. J Clin Oncol 1997;15:2483-2493.
31. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Jr., Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
32. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project b-18. J Natl Cancer Inst Monogr 2001:96-102.
33. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: Results from the european organization for research and treatment of cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
34. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH: Primary systemic therapy of breast cancer. Oncologist 2006;11:574-589.
35. Rouzier R, Mathieu MC, Sideris L, Youmsi E, Rajan R, Garbay JR, Andre F, Marsiglia H, Spielmann M, Delaloge S: Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 2004;101:918-925.
36. Huang EH, Strom EA, Perkins GH, Oh JL, Chen AM, Meric-Bernstam F, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA: Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 2006;66:352-357.
37. Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B: The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of national surgical adjuvant breast and bowel project (nsabp) clinical trials b-04 and b-06. Cancer 2003;98:1362-1368.
38. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P: Second cancers after conservative surgery and radiation for stages i-ii breast cancer: Identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001;51:679-690.
39. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48.
40. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM: Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006;107:1459-1466.
41. Jones RL, Smith IE: Neoadjuvant treatment for early-stage breast cancer: Opportunities to assess tumour response. Lancet Oncol 2006;7:869-874.
42. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Durr-Storzer S, Neubauer H, Wallwiener D, Solomayer EF: Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 2006;8:R60.
43. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-8162.
44. Waterworth A: Introducing the concept of breast cancer stem cells. Breast Cancer Res 2004;6:53-54.
45. Wicha MS, Liu S, Dontu G: Cancer stem cells: An old idea-a paradigm shift. Cancer Res 2006;66:1883-1890; discussion 1895-1886.
46. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-2293.
47. Noguchi S: Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813-820.
48. Andre F, Mazouni C, Hortobagyi GN, Pusztai L: DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. Biochim Biophys Acta 2006.
49. Cinieri S, Orlando L, Colleoni M: Primary systemic therapy on local advance breast cancer, where are we going? Ann Oncol 2006;17 Suppl 7:vii18-vii21.